Nucleus RadioPharma announced the development of two new facilities, totaling over 100,000 square feet, in Mesa, Arizona, and Spring House, Pennsylvania. These state-of-the-art sites will integrate research, development, and commercial production under one roof, providing significant time and scale advantages for Nucleus’ partners. The expansion addresses key challenges in the radiopharmaceutical industry, including a shortage of high-quality manufacturing capabilities and geographic limitations caused by the short half-life of many radiopharmaceuticals. By enabling production closer to patients and clinical trial sites, Nucleus aims to enhance treatment accessibility and accelerate drug development timelines.
To fully realize the potential of theranostic radiopharmaceuticals, they must be available near the patients who need them,” said Nucleus RadioPharma CEO Charles S. Conroy. “Our expansion will significantly improve access to life-saving treatments and speed up clinical trials, potentially reducing the time-to-market for new therapies by up to 30%.”
The 53,000-square-foot Mesa facility and 48,000-square-foot Spring House site are strategically located to serve key markets, with backing from major institutions like Fox Chase Cancer Center and Mayo Clinic. These facilities are expected to create around 50 new jobs at each location, boosting local economies and reinforcing these regions as hubs for healthcare innovation.
Fox Chase Cancer Center CEO Robert Uzzo emphasized the benefits of the new facility, stating, “It will provide faster access to life-saving treatments for patients with limited therapeutic options while contributing to economic growth in the region.”
Mesa Mayor John Giles praised the investment, highlighting the creation of well-paying jobs and the boost to the local economy. He expressed confidence that Nucleus RadioPharma’s expansion would have long-term benefits for the community and patients nationwide.
